Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TOP2A | P11388 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24548242 | 0.75 | HTT (0.38) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31679754 | 0.75 | HTT (0.46) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8795590 | 0.75 | KDM4E (0.50) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11849070 | 0.72 | KDM4E (0.38) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL400496 | 0.71 | MAP4K4 (0.37) | HTTKDM4EHAVCR2GAAPOLB | |
| SCHEMBL11837892 | 0.71 | SMPD3 (0.39) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9936556 | 0.71 | HTT (0.35) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL4301919 | 0.71 | HTT (0.35) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL749849 | 0.71 | KDM4E (0.40) | HTTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL9934743 | 0.71 | HTT (0.35) | HTTKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275965-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | GRITSCIENCE BIOPHARMACEUTICALS CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| WO-2025080788-A1 | CCR4 INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2022127755-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022127755-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | Gritscience Biopharmaceuticals Co., Ltd. (CN) | 2022-06-23 | — | — | WO | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275965-A1 | COMPOUNDS AS CASEIN KINASE INHIBITORS | PACSIN2, CSNK1A1, CSNK1G3 | HTT 3664/4885KDM4E 1702/4885ALDH1A1 4346/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | HTT 4376/4885KDM4E 1316/4885ALDH1A1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.